Clinical Trial Update: A Study of Nivolumab in Selected Uterine Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 study of Nivolumab in selected uterine cancers has completed enrollment and posted results in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma
• Endometrial Clear Cell Carcinoma
• High-grade Endometrial Stromal Sarcoma
• Leiomyosarcoma
• Undifferentiated Sarcoma
• Uterine Cancer
• Uterine Carcinosarcoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Uterine Cancer, Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-27